Pharmaceutical The US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Ryaltris (olopatadine hydrochloride [665mcg] and mometasone furoate [25mcg]), nasal spray, a treatment for seasonal allergic rhinitis (SAR), India’s Glenmark Pharmaceuticals revealed in a Bombay Stock Exchange filing. 25 June 2019